Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EggsAMD
NCT07021027Phase 1Active, not recruiting
- Start
- Jun 2025
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in age-related macular degeneration (AMD) (2 arms). Primary endpoint: Adherence rate to consuming four whole eggs per day at 5 months. Started Jun 2025; status: active, not recruiting.
02
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT07021027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07021027.